MG
ADMA icon

Michael Gelband’s ADMA Biologics ADMA Stock Holding History

Michael Gelband’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-236,724
Closed -$3.47M – 1485
2025
Q3 		$3.47M Sell
236,724
-72,297
-23% -$1.24M 0.04% 537
2025
Q2 		$5.63M Buy
+309,021
New +$6.3M 0.05% 398
2025
Q1 		– Sell
-102,351
Closed -$1.75M – 1404
2024
Q4 		$1.75M Buy
+102,351
New +$1.93M 0.01% 763
2024
Q1 		– Sell
-303,596
Closed -$1.37M – 1450
2023
Q4 		$1.37M Sell
303,596
-99,121
-25% -$367K 0.01% 696
2023
Q3 		$1.44M Buy
402,717
+76,948
+24% +$296K 0.01% 812
2023
Q2 		$1.2M Buy
+325,769
New +$1.21M 0.01% 1031
2023
Q1 		– Sell
-35,632
Closed -$138K – 1706
2022
Q4 		$138K Sell
35,632
-15,857
-31% -$48.9K ﹤0.01% 1495
2022
Q3 		$125K Sell
51,489
-15,109
-23% -$36.2K ﹤0.01% 1717
2022
Q2 		$132K Sell
66,598
-636,553
-91% -$1.25M ﹤0.01% 1713
2022
Q1 		$1.29M Buy
703,151
+680,953
+3,068% +$1.06M 0.02% 997
2021
Q4 		$31K Sell
22,198
-12,499
-36% -$16.4K ﹤0.01% 2064
2021
Q3 		$39K Buy
+34,697
New +$48.6K ﹤0.01% 1988
2021
Q2 		– Sell
-92,360
Closed -$163K – 2280
2021
Q1 		$163K Sell
92,360
-5,296
-5% -$12.1K ﹤0.01% 1908
2020
Q4 		$190K Buy
+97,656
New +$205K ﹤0.01% 1747
2020
Q3 		– Sell
-68,050
Closed -$199K – 1693
2020
Q2 		$199K Sell
68,050
-35,163
-34% -$101K 0.01% 1520
2020
Q1 		$297K Buy
+103,213
New +$357K 0.02% 654
2019
Q2 		– Sell
-15,482
Closed -$59K – 1063
2019
Q1 		$59K Buy
+15,482
New +$54.7K ﹤0.01% 633

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Michael Gelband's ADMA Position: Q4 2025 in Review

Michael Gelband sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 236,724 shares — an estimated $3.47M sold.

Michael Gelband first reported a position in ADMA in Q1 2019 and held it in 17 quarters. The position peaked at $5.63M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Michael Gelband reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Michael Gelband sold 236,724 ADMA Biologics shares in Q4 2025, an estimated $3.47M.
  • Michael Gelband first reported a position in ADMA Biologics in Q1 2019 and held it in 17 quarters.
  • Michael Gelband's ADMA Biologics position peaked at $5.63M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.